Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.mam.2021.100989 | DOI Listing |
Addict Sci Clin Pract
December 2024
Department of General Practice, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Level 5, Prahran, Melbourne, VIC, 3181, Australia.
Background: Family physicians (FPs) are the first point of contact for people who smoke who are seeking to quit smoking in Türkiye. We aimed to explore Turkish FPs knowledge, attitudes and perceptions of e-cigarettes as smoking cessation aids.
Methods: Eleven in-depth semi-structured interviews were conducted with FPs in Istanbul, Türkiye.
Z Evid Fortbild Qual Gesundhwes
December 2024
Arbeitsgruppe Data-Driven Innovation, Technische Universität Hamburg (TUHH), Hamburg, Deutschland. Electronic address:
Background: With the introduction of the Digital Healthcare Act (DVG) at the end of 2019, digital health applications (DiGA) were included in the statutory health insurance in Germany. DiGA are digital medical products whose primary function is based on digital technologies. In the definition of the approval process, the term "therapeutic benefit", which is crucial to the evaluation of pharmaceuticals, was expanded to include the broader concept of "positive healthcare effect" ("pVE").
View Article and Find Full Text PDFJ Ethnobiol Ethnomed
November 2024
Department of Environmental Sciences, Informatics, and Statistics, Ca' Foscari University of Venice, Via Torino 155, 30174, Venice, Italy.
Background: Studies on the in-depth documentation of wild greens use in the Mediterranean Diet (MD) are vital to understanding patterns of cross-geographical change in wild food ingredients in the Mediterranean context, their appreciated taste, and possible evolution. Our present study aims to document the leafy, wild-sourced plant portion of the MD in the unique and isolated matrifocal community of Olympos, North Karpathos Isle, Greece.
Methods: An ethnobotanical field study focussing on traditionally wild-sourced edible greens (chórta) was conducted during the spring of 2023 via 42 semi-structured interviews with local people.
Mol Ther
October 2024
Orphan Medicines Office, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HS Amsterdam, the Netherlands. Electronic address:
To provide insight into regulatory decision-making at the time of granting initial orphan designation by the Committee for Orphan Medicinal Products, we have conducted a retrospective analysis for viral vector-mediated gene therapies in rare non-oncological conditions with respect to the data provided to support the criteria to be met in successful applications. We found that a high proportion of non-clinical in vivo data was used for gene therapies, indicating earlier submissions of products that are at the stage of preclinical research and not in clinical development. Clinical data were submitted in only 13% of the applications, containing preliminary results derived from early-stage clinical trials in few patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!